by Christoph Heinzen, PhD, Andreas Berger, PhD, and Ian Marison, PhD
Volume 3, Issue 2 (March/April 2004)
The first use of mammalian cell culture for the production of vaccines dates back to polio vaccine development in the 1950s. The development of hybridoma technology in the 1970s further stimulated the use of mammalian cells for the production of monoclonal antibodies. Together with developments in genetic engineering, it therefore became possible to produce a wide range of recombinant proteins as well as to improve cell metabolism. Animal cells are now widely used in industrial processes to obtain complex glycoproteins with correct posttranslational modifications and biological activity for diagnostic and therapeutic applications. Animal cells are the main source for commercially available recombinant proteins such as tissue plasminogen activator (tPa), erythropoietin (EPO), DNAse, factor VIII, interferon-ß, and monoclonal antibodies…
Citation:
Heinzen C, Berger A, Marison I. Encapsulating Cells for High-Productivity Recombinant Protein Expression. BioProcess J, 2004; 3(2): 53-56.